Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats

International Journal of Neuropsychopharmacology

Volumn 9, Issue 4, 2006, Pages 427-436

  Orsetti, Marco ^a   Colella, Luciana ^a   Dellarole, Anna ^a   Canonico, Pier Luigi ^a   Ferri, Simona ^b   Ghi, Piera ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Anhedonia; Chronic mild stress; Olanzapine; Rat

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; VALPROIC ACID;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; MENTAL PATIENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SMOKING CESSATION; STRESS; TREATMENT INDICATION;

AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; EATING; HALOPERIDOL; MALE; RATS; RATS, WISTAR; SELF ADMINISTRATION; SUCROSE; VALPROIC ACID;

EID: 33745532054     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570500564X     Document Type: Article

References (31)

1. Brambilla P, Barale F, Soares JC (2003). Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology 166, 315-332.
2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999). Antagonism by olanzapine of dopamine D1, serotonin 2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro. Schizophrenia Research 37, 107-22.
3. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dube S (2003). Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Journal of Clinical Psychiatry 64, 1349-56.
4. Davis LL, Bartolucci A, Petty F (2005). Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders 85, 259-266.
5. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F (1996). Valproate as an antidepressant in major depressive disorder. Psychopharmacology Bulletin 32, 647-652.
6. Drugan RC, Ryan SM, Minor TR, Maier SF (1984). Librium prevents the analgesia and shuttlebox escape deficit typically observed following inescapable shock. Pharmacology, Biochemistry and Behaviour 21, 749-754.
7. Emsley RA, Buckley P, Jones AM, Grenwood MR (2003). Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. Journal of Psychopharmacology 17, 210-215.
8. Ferretti C, Blengio M, Ricci Gamalero S, Ghi P (1995). Biochemical and behaviour changes induced by acute stress in a chronic variate stress model of depression: the effect of amitriptyline. European Journal of Pharmacology 280, 19-26.
9. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK (2000). Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disorders 2, 196-199.
10. Ghi P, Ferretti C, Blengio M (1995). Effects of different types of stress on histamine-H3 receptors in the rat cortex. Brain Research 28, 104-107.
11. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998). 5HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. American Journal of Psychiatry 156, 286-293.
12. Katz R (1982). Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacology, Biochemistry and Behaviour 16, 965-968.
13. Lecrubier Y, Boyer P, Turjanski S, Rein W, Amisulpride Study Group (1997). Amisulpride versus imipramine and placebo in dysthymia and major depression. Journal of Affective Disorders 43, 95-103.
14. Lecrubier Y, Puech AJ, Aubin F, Boyer P, Deyrieux B (1988). Improvement by amisulpride of the negative syndrome in non-psychotic subjects: a preliminary study. Psychiatry and Psychobiology 3, 329-333.
15. Muscat R, Papp M, Willner P (1992). Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology 109, 433-438.
16. Papp M, Moryl E, Willner P (1996). Pharmacological validation of the chronic mild stress model of depression. European Journal of Pharmacology 296, 129-136.
17. Papp M, Wieronska J (2000). Antidepressant-like activity of amisulpride in two animal models of depression. Journal of Psychopharmacology 14, 46-52.
18. Przegalinski E, Moryl E, Papp M (1995). The effect of 5HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology 34, 1305-1310.
19. Sajatovic M, Mullen JA, Sweitzer DE (2002). Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Journal of Clinical Psychiatry 63, 1156-1163.
20. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001). A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 158, 131-134.
21. Sluzewska A, Nowakowska E (1994). The effects of carbamazepine, lithium and ketoconazole in chronic mild stress model of depression in rats. Behavioural Pharmacology 5 (Suppl. 1), 86.
22. Sluzewska A, Szczawinska K (1996). Lithium potentiation of antidepressants in chronic mild stress model of depression in rats. Behavioural Pharmacology 7 (Suppl. 1), 105.
23. Sokolski KN, Denson TF (2003). Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Progress in Neuro- Psychopharmacology and Biological Psychiatry 27, 863-866.
24. Stefanski R, Goldberg SR (1997). Serotonin 5HT2 receptor antagonists-potential in the treatment of psychiatric disorders. Drug Therapy 5, 388-409.
25. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A (2003a). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry 60, 1218-1226.
26. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW (2003b). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry 160, 1263-1271.
27. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003c). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079-1088.
28. Tollefson GD, Beasley CM, Tran PV (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: results of an international collaboration. American Journal of Psychiatry 154, 457-465.
29. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology 93, 358-364.
30. Winsberg ME, DeGolia SG, Strong CM, Ketter TA (2001). Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. Journal of Affective Disorders 67, 207-212.
31. Zarate CA, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S (1998). Clinical predictors of acute response with olanzapine in psychotic mood disorders. Journal of Clinical Psychiatry 59, 24-28.